Neural correlates of chemotherapy-related cognitive impairment

Cortex

Volumn 54, Issue 1, 2014, Pages 33-50

  Kaiser, Jochen ^a   Bledowski, Christoph ^a   Dietrich, Jörg ^b  

^a GOETHE UNIVERSITY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Cognitive deficits; Event related potentials; Functional imaging; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CARMOFUR; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TEMOZOLOMIDE; THIOTEPA;

BRAIN; BRAIN FUNCTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FUNCTIONAL NEUROIMAGING; HEMODYNAMICS; HUMAN; LEARNING DISORDER; MEMORY DISORDER; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; REVIEW; WHITE MATTER LESION; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; NEOPLASMS; NEUROIMAGING; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; NEUROIMAGING;

EID: 84896042587     PISSN: 00109452     EISSN: 19738102     Source Type: Journal    
DOI: 10.1016/j.cortex.2014.01.010     Document Type: Review

References (143)

1. Abraham J., Haut M.W., Moran M.T., Filburn S., Lemiuex S., Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clinical Breast Cancer 2008, 8(1):88-91.
2. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer 2007, 7(3):192-201.
3. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology 2002, 20(2):485-493.
4. Ahles T.A., Saykin A.J., McDonald B.C., Furstenberg C.T., Cole B.F., Hanscom B.S., et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treatment 2008, 110(1):143-152.
5. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha V.B., Compas B.E. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. Journal of the International Neuropsychological Society 2003, 9(7):967-982.
6. Aron A.R., Gluck M.A., Poldrack R.A. Long-term test-retest reliability of functional MRI in a classification learning task. NeuroImage 2006, 29(3):1000-1006.
7. Basser P.J., Mattiello J., LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophysics Journal 1994, 66(1):259-267.
8. Bender C.M., Sereika S.M., Berga S.L., Vogel V.G., Brufsky A.M., Paraska K.K., et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006, 15(5):422-430.
9. Bennett C.M., Miller M.B. How reliable are the results from functional magnetic resonance imaging?. Annals of the New York Academy of Science 2010, 1191:133-155.
10. Bisen-Hersh E.B., Hineline P.N., Walker E.A. Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivors. Clinical Cancer Research 2013, 19(11):3008-3018.
11. Bledowski C., Kaiser J., Rahm B. Basic operations in working memory: contributions from functional imaging studies. Behavioural Brain Research 2010, 214(2):172-179.
12. Bledowski C., Prvulovic D., Hoechstetter K., Scherg M., Wibral M., Goebel R., et al. Localizing P300 generators in visual target and distractor processing: a combined event-related potential and functional magnetic resonance imaging study. Journal of Neuroscience 2004, 24(42):9353-9360.
13. Brown M.S., Simon J.H., Stemmer S.M., Stears J.C., Scherzinger A., Cagnoni P.J., et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR American Journal of Neuroradiology 1995, 16(10):2013-2020.
14. Brown M.S., Stemmer S.M., Simon J.H., Stears J.C., Jones R.B., Cagnoni P.J., et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR American Journal of Neuroradiology 1998, 19(2):217-221.
15. Bruno J., Hosseini S.M., Kesler S. Altered resting statefunctional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiology of Disease 2012, 48(3):329-338.
16. Button K.S., Ioannidis J.P., Mokrysz C., Nosek B.A., Flint J., Robinson E.S., et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 2013, 14(5):365-376.
17. Caceres A., Hall D.L., Zelaya F.O., Williams S.C., Mehta M.A. Measuring fMRI reliability with the intra-class correlation coefficient. NeuroImage 2009, 45(3):758-768.
18. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology 2004, 26(7):955-969.
19. Christie L.A., Acharya M.M., Parihar V.K., Nguyen A., Martirosian V., Limoli C.L. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clinical Cancer Research 2012, 18(7):1954-1965.
20. Ciesielski K.T., Lesnik P.G., Benzel E.C., Hart B.L., Sanders J.A. MRI morphometry of mamillary bodies, caudate nuclei, and prefrontal cortices after chemotherapy for childhood leukemia: multivariate models of early and late developing memory subsystems. Behavioral Neuroscience 1999, 113(3):439-450.
21. Cimprich B., Reuter-Lorenz P., Nelson J., Clark P.M., Therrien B., Normolle D., et al. Prechemotherapy alterations in brain function in women with breast cancer. Journal of Clinical and Experimental Neuropsychology 2010, 32(3):324-331.
22. Collette F., Hogge M., Salmon E., Van der Linden M. Exploration of the neural substrates of executive functioningby functional neuroimaging. Neuroscience 2006, 139(1):209-221.
23. Conroy S.K., McDonald B.C., Smith D.J., Moser L.R., West J.D., Kamendulis L.M., et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Research and Treatment 2013, 137(2):493-502.
24. Damoiseaux J.S., Rombouts S.A., Barkhof F., Scheltens P., Stam C.J., Smith S.M., et al. Consistent resting-state networks across healthy subjects. Proceedings of the National Academy of Sciences of the U S A 2006, 103(37):13848-13853.
25. Deprez S., Amant F., Smeets A., Peeters R., Leemans A., Van Hecke W., et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. Journal of Clinical Oncology 2012, 30(3):274-281.
26. Deprez S., Amant F., Yigit R., Porke K., Verhoeven J., Van den Stock J., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human Brain Mapping 2011, 32(3):480-493.
27. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents invitro and invivo. Journal of Biology 2006, 5(7):22.
28. Dietrich J., Monje M., Wefel J., Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13(12):1285-1295.
29. Dietrich J., Wen P. Neurological complications of chemotherapy. Cancer Neurology in Clinical Practice 2008, 287-326. Humana Press, Totowa, NJ. D. Schiff, S. Kesari, P. Wen (Eds.).
30. Enriquez-Geppert S., Huster R.J., Herrmann C.S. Boosting brain functions: improving executive functions with behavioral training, neurostimulation, and neurofeedback. International Journal of Psychophysiology 2013, 88(1):1-16.
31. Erickson K.I., Voss M.W., Prakash R.S., Basak C., Szabo A., Chaddock L., et al. Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Science of the U S A 2011, 108(7):3017-3022.
32. Falleti M.G., Sanfilippo A., Maruff P., Weih L., Phillips K.A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain and Cognition 2005, 59(1):60-70.
33. Fardell J.E., Vardy J., Johnston I.N. The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sciences 2013, 93(17):596-604.
34. Fardell J.E., Vardy J., Shah J.D., Johnston I.N. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 2012, 220(1):183-193.
35. Ferguson R.J., Ahles T.A., Saykin A.J., McDonald B.C., Furstenberg C.T., Cole B.F., et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007, 16(8):772-777.
36. Ferguson R.J., McDonald B.C., Saykin A.J., Ahles T.A. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. Journal of Clinical Oncology 2007, 25(25):3866-3870.
37. Ferreira F.N., Andrade A.G., Alves T.C.T.F. Neuroimaging findings in breast cancer: a systematic qualitative review. International Journal of Medicine and Medical Sciences 2009, 1(10):442-447.
38. Fliessbach K., Helmstaedter C., Urbach H., Althaus A., Pels H., Linnebank M., et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005, 64(7):1184-1188.
39. Fliessbach K., Urbach H., Helmstaedter C., Pels H., Glasmacher A., Kraus J.A., et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Archives of Neurology 2003, 60(4):563-568.
40. Friston K. Causal modelling and brain connectivity in functional magnetic resonance imaging. PLoS Biology 2009, 7(2):e33.
41. Fulham M.J., Brunetti A., Aloj L., Raman R., Dwyer A.J., Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. Journal of Neurosurgery 1995, 83(4):657-664.
42. Gandal M.J., Ehrlichman R.S., Rudnick N.D., Siegel S.J. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008, 157(1):95-104.
43. Gibson E., Monje M. Effect of cancer therapy on neural stem cells: implications for cognitive function. Current Opinion in Oncology 2012, 24(6):672-678.
44. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms inDNA repair genes and associations with cancer risk. Cancer Epidemiology Biomarkers & Prevention 2002, 11(12):1513-1530.
45. Hampstead B.M., Stringer A.Y., Stilla R.F., Giddens M., Sathian K. Mnemonic strategy training partially restores hippocampal activity in patients with mild cognitive impairment. Hippocampus 2012, 22(8):1652-1658.
46. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Proschel M., Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology 2008, 7(4):12.
47. Harder H., Holtel H., Bromberg J.E., Poortmans P., Haaxma-Reiche H., Kluin-Nelemans H.C., et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62(4):544-547.
48. Hede K. Chemobrain is real but may need new name. Journal of the National Cancer Institute 2008, 100(3). 162-163, 169.
49. Hermelink K., Henschel V., Untch M., Bauerfeind I., Lux M.P., Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008, 113(9):2431-2439.
50. Hermelink K., Kuchenhoff H., Untch M., Bauerfeind I., Lux M.P., Buhner M., et al. Two different sides of'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010, 19(12):1321-1328.
51. Hermelink K., Untch M., Lux M.P., Kreienberg R., Beck T., Bauerfeind I., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007, 109(9):1905-1913.
52. Herrera C., Chambon C., Michel B.F., Paban V., Alescio-Lautier B. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. Neuropsychologia 2012, 50(8):1871-1881.
53. Herschbach P., Book K., Brandl T., Keller M., Lindena G., Neuwohner K., et al. Psychological distress in cancer patients assessed with an expert rating scale. British Journal of Cancer 2008, 99(1):37-43.
54. Heukrodt C., Powazek M., Brown W.S., Kennelly D., Imbus C., Robinson H., et al. Electrophysiological signs of neurocognitive deficits in long-term leukemia survivors. Journal of Pediatric Psychology 1988, 13(2):223-236.
55. Hutchinson A.D., Hosking J.R., Kichenadasse G., Mattiske J.K., Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treatment Reviews 2012, 38(7):926-934.
56. Hyrien O., Dietrich J., Noble M. Mathematical and experimental approaches to identify and predict the effects of chemotherapy on neuroglial precursors. Cancer Research 2010, 70(24):10051-10059.
57. Inagaki M., Yoshikawa E., Matsuoka Y., Sugawara Y., Nakano T., Akechi T., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109(1):146-156.
58. Jaeggi S.M., Buschkuehl M., Jonides J., Perrig W.J. Improving fluid intelligence with training on working memory. Proceedings of the National Academy of Science of the U S A 2008, 105(19):6829-6833.
59. Jansen C.E., Miaskowski C., Dodd M., Dowling G., Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005, 104(10):2222-2233.
60. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., et al. A 3-year prospective study of the effectsof adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer 2006, 94(6):828-834.
61. Jones D.K., Knösche T.R., Turner R. White matter integrity, fiber count, and other fallacies: the do's and don'ts of diffusion MRI. NeuroImage 2013, 73:239-254.
62. Juergens A., Pels H., Rogowski S., Fliessbach K., Glasmacher A., Engert A., et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Annals of Neurology 2010, 67(2):182-189.
63. Kaiser J., Ripper B., Birbaumer N., Lutzenberger W. Dynamics of gamma-band activity in human magnetoencephalogram during auditory pattern working memory. NeuroImage 2003, 20(2):816-827.
64. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters 2006, 234(1):4-33.
65. Kesler S.R., Bennett F.C., Mahaffey M.L., Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clinical Cancer Research 2009, 15(21):6665-6673.
66. Kesler S.R., Kent J.S., O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Archives of Neurology 2011, 68(11):1447-1453.
67. Kesler S.R., Wefel J.S., Hosseini S.M., Cheung M., Watson C.L., Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proceedings of the National Academy of Science of the U S A 2013, 110(28):11600-11605.
68. Kingma A., van Dommelen R.I., Mooyaart E.L., Wilmink J.T., Deelman B.G., Kamps W.A. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. Journal of Pediatrics 2001, 139(3):413-420.
69. Kok A. On the utility of P3 amplitude as a measure of processing capacity. Psychophysiology 2001, 38(3):557-577.
70. Koppelmans V., Breteler M.M., Boogerd W., Seynaeve C., Gundy C., Schagen S.B. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology 2012, 30(10):1080-1086.
71. Koppelmans V., de Ruiter M.B., van der Lijn F., Boogerd W., Seynaeve C., van der Lugt A., et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Research and Treatment 2012, 132(3):1099-1106.
72. Koppelmans V., de Groot M.D., de Ruiter M.B., Boogerd W., Seynaeve C., Vernooij M.W., et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Human Brain Mapping 2014, 35(3):889-899.
73. Kreukels B.P., Hamburger H.L., de Ruiter M.B., van Dam F.S., Ridderinkhof K.R., Boogerd W., et al. ERP amplitudeand latency in breast cancer survivors treated with adjuvant chemotherapy. Clinical Neurophysiology 2008, 119(3):533-541.
74. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., Muller M.J., et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clinical Breast Cancer 2006, 7(1):67-78.
75. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., van Dam F.S. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Research and Treatment 2005, 94(1):53-61.
76. Kreukels B.P., van Dam F.S., Ridderinkhof K.R., Boogerd W., Schagen S.B. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clinical Breast Cancer 2008, 8(1):80-87.
77. Krynetskiy E., Krynetskaia N., Rihawi D., Wieczerzak K., Ciummo V., Walker E. Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment. Life Sciences 2013, 93(17):605-610.
78. Lachaux J.P., Rodriguez E., Martinerie J., Varela F.J. Measuring phase synchrony in brain signals. Human Brain Mapping 1999, 8(4):194-208.
79. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clinical Cancer Research 2006, 12(1):198-205.
80. Lesnik P.G., Ciesielski K.T., Hart B.L., Benzel E.C., Sanders J.A. Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model. Archives of Neurology 1998, 55(12):1561-1568.
81. Linden D.E. The p300: where in the brain is it produced and what does it tell us?. Neuroscientist 2005, 11(6):563-576.
82. Linden D.E. The working memory networks of the human brain. Neuroscientist 2007, 13(3):257-267.
83. Luck S.J., Mathalon D.H., O'Donnell B.F., Hamalainen M.S., Spencer K.M., Javitt D.C., et al. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biological Psychiatry 2011, 70(1):28-34.
84. Lutzenberger W., Ripper B., Busse L., Birbaumer N., Kaiser J. Dynamics of gamma-band activity during an audiospatial working memory task in humans. Journal of Neuroscience 2002, 22(13):5630-5638.
85. Macleod J.E., DeLeo J.A., Hickey W.F., Ahles T.A., Saykin A.J., Bucci D.J. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behavioural Brain Research 2007, 181(1):168-172.
86. Mathalon D.H., Ford J.M., Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biological Psychiatry 2000, 47(5):434-449.
87. Matsuda T., Takayama T., Tashiro M., Nakamura Y., Ohashi Y., Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005, 12(4):279-287.
88. Mayerhofer K., Bodner K., Saletu B., Bodner-Adler B., Anderer P., Hefler L., et al. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Anticancer Research 2001, 21(1B):803-808.
89. McDonald B.C., Conroy S.K., Ahles T.A., West J.D., Saykin A.J. Gray matter reduction associated withsystemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Research and Treatment 2010, 123(3):819-828.
90. McDonald B.C., Conroy S.K., Ahles T.A., West J.D., Saykin A.J. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. Journal of Clinical Oncology 2012, 30(20):2500-2508.
91. McDonald B.C., Conroy S.K., Smith D.J., West J.D., Saykin A.J. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain, Behavior, and Immunity 2013, 30(Suppl.):S117-S125.
92. Mehlsen M., Pedersen A.D., Jensen A.B., Zachariae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 2009, 18(3):248-257.
93. Monje M., Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behavioural Brain Research 2012, 227(2):376-379.
94. Morcom A.M., Fletcher P.C. Does the brain have a baseline? Why we should be resisting a rest. NeuroImage 2007, 37(4):1073-1082.
95. Naumer M.J., van den Bosch J.J., Wibral M., Kohler A., Singer W., Kaiser J., et al. Investigating human audio-visual object perception with a combination of hypothesis-generating and hypothesis-testing fMRI analysis tools. Experimental Brain Research 2011, 213(2-3):309-320.
96. Nee D.E., Jonides J. Neural evidence for a 3-state model of visual short-term memory. NeuroImage 2013, 74C:1-11.
97. Nokia M.S., Anderson M.L., Shors T.J. Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain. European Journal of Neuroscience 2012, 36(11):3521-3530.
98. Nokia M.S., Penttonen M., Korhonen T., Wikgren J. Hippocampal theta-band activity and trace eyeblink conditioning in rabbits. Behavioral Neuroscience 2009, 123(3):631-640.
99. Polich J. Clinical application of the P300 event-related brain potential. Physical Medicine and Rehabilitation Clinics of North America 2004, 15(1):133-161.
100. Polich J. Updating P300: an integrative theory of P3a and P3b. Clinical Neurophysiology 2007, 118(10):2128-2148.
101. Poppelreuter M., Weis J., Kulz A.K., Tucha O., Lange K.W., Bartsch H.H. Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre. European Journal of Cancer 2004, 40(1):43-49.
102. Raffa R.B. Imaging as a means of studying chemotherapy-related cognitive impairment. Advances in Experimental Medicine and Biology 2010, 678:70-76.
103. Reiriz A.B., Reolon G.K., Preissler T., Rosado J.O., Henriques J.A., Roesler R., et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clinical Cancer Research 2006, 12(16):5000. author reply 5000-5001.
104. de Ruiter M.B., Reneman L., Boogerd W., Veltman D.J., Caan M., Douaud G., et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Human Brain Mapping 2012, 33(12):2971-2983.
105. de Ruiter M.B., Reneman L., Boogerd W., Veltman D.J., van Dam F.S., Nederveen A.J., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping 2011, 32(8):1206-1219.
106. Reuter-Lorenz P.A., Cimprich B. Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Research and Treatment 2013, 137(1):33-43.
107. Roebroeck A., Formisano E., Goebel R. Mapping directed influence over the brain using Granger causality and fMRI. NeuroImage 2005, 25(1):230-242.
108. Salminen T., Strobach T., Schubert T. On the impacts of working memory training on executive functioning. Frontiers in Human Neuroscience 2012, 6:166.
109. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry 2003, 8(4):201-216.
110. Schagen S.B., Boogerd W., Muller M.J., Huinink W.T., Moonen L., Meinhardt W., et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncologica 2008, 47(1):63-70.
111. Schagen S.B., Hamburger H.L., Muller M.J., Boogerd W., van Dam F.S. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. Journal of Neurooncology 2001, 51(2):159-165.
112. Schagen S.B., van Dam F.S., Muller M.J., Boogerd W., Lindeboom J., Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999, 85(3):640-650.
113. Scherling C., Collins B., Mackenzie J., Bielajew C., Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. Frontiers in Human Neuroscience 2011, 5:122.
114. Schneiders J.A., Opitz B., Tang H., Deng Y., Xie C., Li H., et al. The impact of auditory working memory training on the fronto-parietal working memory network. Frontiers in Human Neuroscience 2012, 6:173.
115. Seigers R., Fardell J.E. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neuroscience and Biobehavioral Reviews 2011, 35(3):729-741.
116. Seigers R., Schagen S.B., Beerling W., Boogerd W., van Tellingen O., van Dam F.S., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behavioural Brain Research 2008, 186(2):168-175.
117. Seigers R., Schagen S.B., Van Tellingen O., Dietrich J. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging and Behavior 2013, 7(4):453-459.
118. Shilling V., Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing 2007, 11(1):6-15.
119. Silberfarb P.M. Chemotherapy and cognitive defects in cancer patients. Annual Review of Medicine 1983, 34:35-46.
120. Silverman D.H., Dy C.J., Castellon S.A., Lai J., Pio B.S., Abraham L., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Research and Treatment 2007, 103(3):303-311.
121. Simon S.S., Yokomizo J.E., Bottino C.M. Cognitive intervention in amnestic mild cognitive impairment: a systematic review. Neuroscience and Biobehavioral Reviews 2012, 36(4):1163-1178.
122. Simo M., Rifa-Ros X., Rodriguez-Fornells A., Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neuroscience and Biobehavioral Reviews 2013, 37(8):1311-1321.
123. Sinha R., Bernardy N., Parsons O.A. Long-term test-retest reliability of event-related potentials in normals and alcoholics. Biological Psychiatry 1992, 32(11):992-1003.
124. Stemmer S.M., Stears J.C., Burton B.S., Jones R.B., Simon J.H. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. American Journal of Neuroradiology 1994, 15(7):1267-1273.
125. Stewart A., Bielajew C., Collins B., Parkinson M., Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clinical Neuropsychology 2006, 20(1):76-89.
126. Taillibert S., Voillery D., Bernard-Marty C. Chemobrain: is systemic chemotherapy neurotoxic?. Current Opinion in Oncology 2007, 19(6):623-627.
127. Takeuchi H., Sekiguchi A., Taki Y., Yokoyama S., Yomogida Y., Komuro N., et al. Training of working memory impacts structural connectivity. Journal of Neuroscience 2010, 30(9):3297-3303.
128. Takeuchi H., Taki Y., Kawashima R. Effects of working memory training on cognitive functions and neural systems. Reviews in the Neurosciences 2010, 21(6):427-449.
129. Tangpong J., Cole M.P., Sultana R., Estus S., Vore M., St Clair W., et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. Journal of Neurochemistry 2007, 100(1):191-201.
130. Uhlhaas P.J., Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 2006, 52(1):155-168.
131. Vardy J., Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Critical Reviews in Oncology Hematology 2007, 63(3):183-202.
132. Vardy J., Wefel J.S., Ahles T., Tannock I.F., Schagen S.B. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology 2008, 19(4):623-629.
133. Walker C.H., Drew B.A., Antoon J.W., Kalueff A.V., Beckman B.S. Neurocognitive effects of chemotherapyand endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Investigation 2012, 30(2):135-148.
134. Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. 'Chemobrain' in breast carcinoma?: A prologue. Cancer 2004, 101(3):466-475.
135. Wefel J.S., Saleeba A.K., Buzdar A.U., Meyers C.A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116(14):3348-3356.
136. Wefel J.S., Schagen S.B. Chemotherapy-related cognitive dysfunction. Current Neurology and Neuroscience Reports 2012, 12(3):267-275.
137. Weiss H.D., Walker M.D., Wiernik P.H. Neurotoxicity of commonly used antineoplastic agents (first of two parts). New England Journal of Medicine 1974, 291(2):75-81.
138. Wibral M., Rahm B., Rieder M., Lindner M., Vicente R., Kaiser J. Transfer entropy in magnetoencephalographic data: quantifying information flow in cortical and cerebellar networks. Progress in Biophysics and Molecular Biology 2011, 105(1-2):80-97.
139. Wieneke M.H., Dienst E.R. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995, 4(1):61-66.
140. Winocur G., Henkelman M., Wojtowicz J.M., Zhang H., Binns M.A., Tannock I.F. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clinical Cancer Research 2012, 18(11):3112-3121.
141. Winocur G., Vardy J., Binns M.A., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacology Biochemistry and Behavior 2006, 85(1):66-75.
142. Yoshikawa E., Matsuoka Y., Inagaki M., Nakano T., Akechi T., Kobayakawa M., et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Research and Treatment 2005, 92(1):81-84.
143. Zandbelt B.B., Gladwin T.E., Raemaekers M., van Buuren M., Neggers S.F., Kahn R.S., et al. Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size. NeuroImage 2008, 42(1):196-206.